10% formalin solution; ir 3575 (OH), 1720, 1650 (CO), 1530, 1340 (NO_2), 1020 and 965 cm^{-1} (nitrofuran).

4,5-Dihydro-6-(5-nitro-2-furyl)-*as*-triazin-3(2H)-one (28).—Extreme caution should be used during the performance of this reaction. An ice–H_2O bath should be available.

A 500-ml three-neck flask, fitted with a thermometer and a stirrer, was charged with 10.0 g (0.06 mol) of finely pulverized 4,5-dihydro-6-(2-furyl)-*as*-triazine-3(2H)-one[5] and 300 ml of $CHCl_3$. The suspension was heated to boiling with stirring and then allowed to cool to 50°. With continued stirring, 15 ml of concentrated HNO_3 (sp gr 1.42) was added slowly in about 1-ml portions. When the addition was completed (*ca.* 5 min), the stirrer was temporarily stopped. A globular material accumulated on the $CHCl_3$ surface. The instant coalescence began (observed by vigorous bubbling with evolution of brown fumes), the stirrer was started, and an ice–H_2O bath was raised around the flask. After chilling the dark red homogeneous solution to 10°, 150 ml of cold H_2O was added in one portion. The product separated instantly as yellow crystals which were filtered off, washed thoroughly with cold H_2O, and air dried; ir 3225 (NH), 1695 (CO), 1515, 1345 (NO_2), 1023 and 962 cm^{-1} (nitrofuran).

6-(5-Nitro-2-furyl)-3-thio-*as*-triazine-3,5(2H,4H)-dione (29).—To 400 ml of cold (10°) concentrated H_2SO_4 was added 60.0 g (0.30 mol) of **8** in portions with stirring. After cooling to −5°, a chilled solution of 25 ml of concentrated HNO_3 (sp gr 1.42) in 40 ml of concentrated H_2SO_4 was added dropwise with stirring at such a rate that the temperature was kept below −5°. The addition required 30–40 min. Stirring was continued below 0° for 1 hr after which the mixture was poured cautiously into 3 l. of ice–H_2O. The crystallized product was filtered off and washed thoroughly with H_2O; ir 3150 (NH), 1682 (CO), 1515, 1343 (NO_2), 1018 and 967 cm^{-1} (nitrofuran).

By means of a similar procedure compounds **30** and **31** were prepared from **9** and **10**, respectively.

3-Acetamido-6-(5-nitro-2-furyl)-*as*-triazin-5(4H)-one (36). To 160 ml of fuming (90%) HNO_3 was added 22.4 g (0.11 mol) of **14** in small portions with stirring below 10°. The solution was kept in the cold for 0.5 hr after which it was poured cautiously into 1 l. of ice–H_2O. The crystallized product was filtered off and washed thoroughly with cold H_2O; ir 3150 (NH), 1700, 1638 (CO), 1528, 1360 (NO_2), 1020 and 967 cm^{-1} (nitrofuran).

3-Imino-6-(5-nitro-2-furyl)-*as*-triazine-3,5(2H,4H)-dione (35).—A suspension of 70.0 g (0.30 mol) of **36** in 1 l. of 20% aqueous HCl was refluxed for 6 hr. The solution was cooled and the tan solid filtered off and washed with H_2O; ir 3420 (NH), 1655 (C=N), 1625 (CO), 1528, 1340 (NO_2), 1015 and 967 cm^{-1} (nitrofuran).

Acknowledgments.—I am grateful to Mr. G. Gustin and Mr. M. Tefft for the elemental analyses, to members of the Chemotherapy Division for the screening results, to Mr. W. O. Smith for assistance in the preparation of the compounds, and to Mr. B. F. Stevenson and associates for large scale synthetic support.

(5) D. G. Holland and E. D. Amstutz, *Rec. Trav. Chim.*, **83**, 1047 (1964).

Nitrofuryl Heterocycles. XI.[1] 3-(5-Nitro-2-furyl)-Δ^2-1,2,4-triazolin-5-ones.

LOUIS E. BENJAMIN, HOMER A. BURCH,[2]

Chemistry Division

AND RICHARD DOBSON

Chemotherapy Division, The Norwich Pharmacal Company, Norwich, New York, 13815

Received November 3, 1969

As part of our investigation of the potential antibacterial properties of nitrofuryl heterocycles, methods were evaluated for the preparation of nitrofuryl 1,2,4-triazole derivatives. An earlier paper presented our explorations of 3-alkyl-5-(5-nitro-2-furyl)-1,2,4-triazoles.[3] This note presents our work on the preparation and testing of 3-(5-nitro-2-furyl)-Δ^2-1,2,4-triazolin-5-ones.

Initial routes to this ring system by decarboxylative cyclization of 2-furanglyoxylic acid semicarbazone[1] in alkaline KI–I_2 solution, ring closure of 2-furaldehyde semicarbazone with either $FeCl_3$ or $K_3Fe(CN)_6$, thermal or P_2O_5 dehydration of 2-furoic acid semicarbazide,[4] or alkaline rearrangement of 2-amino-5-(2-furyl)-1,3,4-oxadiazole[5,6] proved undesirable. However, by a modification of the method of Pesson, *et al.*,[7] the intermediate 5-nitro-*N*-uredio-2-furamidine hydrochlorides, obtained from the reaction of ethyl 5-nitro-2-furimidate hydrochloride (**1**)[8] with various semicarbazides, readily cyclized in refluxing $PhNO_2$ to give the Δ^2-1,2,4-triazolin-5-ones **6–9**. Difficulties in purification made it necessary to characterize the 5-nitro-*N*-ureido-2-furamidine hydrochlorides as their free bases (**2–5**). With the exception of **2** the free bases failed to cyclize when heated to 200° in $PhNO_2$.



Although cyclization of the 5-nitro-*N*-ureido-2-furamidines could lead to the isomeric 2-amino- or 2-imino-1,3,4-oxadiazole structures, the presence of carbonyl absorption at 1690 cm^{-1} in the ir and their failure to form HCl salts indicated that **6–9** are best represented by the Δ^2-1,2,4-triazolin-5-one structure. The nmr spectra of compounds **6–9** were also consistent with this structure assignment. Finally, an authentic sample of 2-amino-5-(5-nitro-2-furyl)-1,3,4-oxadiazole[9] was prepared from 5-nitro-2-furoylhydrazine and CNBr. It showed no absorption in the 1670–1790 cm^{-1} region and showed a depression of the melting point on admixture with **6**.

Table I summarizes the physical properties of the compounds prepared. The antibacterial testing data, obtained by standard procedures, on compounds **6–9** are summarized in Table II.

Experimental Section[10]

5-Nitro-*N*-ureido-2-furamidine (2).—A mixture of 100 g (0.45 mol) of **1**,[8] 34 g (0.45 mol) of semicarbazide, and 800 ml of absolute EtOH was heated at 50–60° for 30 min with occasional stirring.

(1) For the previous paper in this series see H. A. Burch, *J. Med. Chem.*, **13**, 288(1970).

(2) To whom inquires concerning this paper should be addressed.

(3) H. A. Burch and W. O. Smith, *J. Med. Chem.*, **9**, 405 (1966).

(4) H. L. Yale, K. A. Losee, F. M. Perry, and J. Bernstein, *J. Amer. Chem. Soc.*, **76**, 2208 (1954).

(5) H. L. Yale and K. Losee, *J. Med. Chem.*, **9**, 478 (1966).

(6) J. C. Howard and H. A. Burch, *J. Org. Chem.*, **26**, 1651 (1961).

(7) M. Pesson, S. Dupin, and M. Antoine, *Bull. Soc. Chim. Fr.*, 1364 (1962).

(8) W. R. Sherman and A. von Esch, *J. Med. Chem.*, **8**, 25 (1965).

(9) W. R. Sherman, *J. Org. Chem.*, **26**, 88 (1961).

(10) All melting points were determined in open capillaries using a Mel-Temp melting point apparatus and are corrected. Ir spectra were determined as Nujol mulls on a Perkin–Elmer Model 135 Infracord. The nmr spectra were obtained on a Varian A60A instrument using Me_4Si as an internal standard.

TABLE I



No.	R	Mp, °C	Yield, %	Recrystn solvent	Formula[a]
2	H	274–275	51	DMF–MeCN	$C_6H_7N_5O_4$
3	CH_3	195–196	64	MeOH or DMF	$C_7H_9N_5O_4$
4	CH_2CH_3	173–174	60	H_2O	$C_8H_{11}N_5O_4$
5	CH_2CH_2OH	181–182	40	MeOH	$C_8H_{11}N_5O_5$



6	H	277–279	78	H_2O	$C_6H_4N_4O_4$
7	CH_3	275–276	73	H_2O	$C_7H_6N_4O_4$
8	CH_2CH_3	243–244	56	AcOH	$C_8H_8N_4O_4$
9	CH_2CH_2OH	263–264	38	AcOH	$C_8H_8N_4O_5$

[a] All compounds analyzed for C, H, and N within ±0.40% of the theoretical values.

TABLE II

ANTIBACTERIAL TESTING OF 3-(5-NITRO-2-FURYL)-Δ^2-1,2,4-TRIAZOLIN-5-ONES

	Minimal inhibitory concentration, μg ml[a]								
No.	Mi-6[b]	Es-2	Ps-10	Pr-12	SaD-13	StA-1	StB-12	Er-4	Ae-6
6	200	10	>200	>200	100	12.5	100	12.5	>200
7	25	3.1	>200	>200	6.25	25	>200	3.1	200
8	25	12.5	>100	>100	12.5	100	>100	6.25	>100
9	6.25	0.38	>50	>50	3.1	50	>50	3.1	>50
Nitrofurazone[c]	12.5	3	>100	100	3	6	12.5	12.5	100

[a] Minimal inhibitory concentration is the lowest concentration of compound that prevents visible growth after 24 hr of incubation. [b] The Norwich Pharmacal Co. strain number: Mi-6 = *Staphylococcus aureus*, Es-2 = *Escherichia coli*, Ps-10 = *Pseudomonas aeruginosa*, Pr-12 = *Proteus vulgaris*, SaD-13 = *Salmonella typhosa*, StA-1 = *Streptococcus pyogenes*, StB-12 = *Streptococcus agalactiae*, Er-4 = *Erysipelothrix insidiosa*, Ae-6 = *Aerobacter aerogenes*. [c] Furacin(R), for comparison.

The mixture was cooled to room temperature and filtered. The orange solid was washed successively with H_2O, *i*-PrOH, and Et_2O and then air dried. A warm solution of the crude salt in DMF was diluted with MeCN and kept at room temperature until crystallization was complete. Conversion of the salt into the free base **2** was effected with aqueous Na_2CO_3 solution.

Compounds **3–5** were prepared similarly from **1** and the appropriately 2-substituted semicarbazides except that the crude salts were obtained by dilution of the reaction mixtures with Et_2O.

3-(5-Nitro-2-furyl)-Δ^2-1,2,4-triazolin-5-one (6).—A solution of 60 g (0.28 mol) of **2**·HCl in 450 ml of $PhNO_2$ was refluxed for 15 min, cooled, and diluted with 400 ml of Et_2O. The dark solid was filtered off, washed with Et_2O, and dried.

Compounds **7–9** were prepared similarly from the appropriate intermediates **3–5**.

Acknowledgments.—The authors are grateful to Mr. G. Gustin and Mr. M. Tefft for the elemental analyses and to Mrs. P. Curtis for the nmr spectra.

Synthesis of 1-Phenyl-2-styryl-3,5-dioxopyrazolidines as Antiinflammatory Agents

HISAO YAMAMOTO AND SHIN-ICHI KANEKO

Pharmaceuticals Division, Sumitomo Chemical Co., Ltd., Osaka, Japan

Received July 11, 1969

A series of 1-phenyl-2-styryl-3,5-dioxopyrazolidine derivatives was synthesized for antiinflammatory testing, and it was found that some of these compounds were more potent inhibitors than phenylbutazone or oxyphenbutazone in the carrageenin-induced foot edema test in rats.

In a previous paper,[1] it was reported that 1,2-pentylmalonyl-1,2-dihydro-4-phenylcinnoline (I) showed potent antiinflammatory activity. This prompted us to prepare 1-phenyl-2-styryl-3,5-dioxopyrazolidines (II), because the intrinsic antiinflammatory activity of I might be due to the presence of a 3,5-dioxopyrazolidine ring and the activity might be kept when the C_6–C_{6a} bond of I is cleaved. Based on this hypothesis, various derivatives of II have been prepared for antiinflammatory tests.[2]



I



II

Compounds (II) based on the same concept were recently suggested to have antiinflammatory activity, though their synthesis has not been described.[3]

(1) U. Jahn and Th. Wagner-Jauregg, *Arzneim. Forsch.*, **18**, 120(1948).

(2) H. Yamamoto and S. Kaneko, Japan Patent Application No. 68-5501 and 68-5815 (Aug 1968).

(3) F. Schatz und Th. Wagner-Jauregg, *Helv. Chim. Acta*, **51**, 1919 (1968).